Yuhan Corporation engaged in discussions with basic science researchers regarding collaboration for new drug development.
On September 18, Yuhan held the '4th Yuhan Innovation Program (YIP) Networking Day' at its cultural complex, Willow House, to commemorate its 100th anniversary.
Approximately 50 attendees participated, including Yuhan CEO Joo Ok-je and Kim Yeol-hong, head of research and development (R&D), along with R&D executives, key researchers, and YIP project leaders. Participants shared updates on YIP projects and explored potential future collaborations.
Since 2022, Yuhan has operated the YIP, a program supporting basic research aimed at innovative drug development. YIP is an open innovation initiative that backs creative research ideas proposed by researchers from domestic universities and public research institutions, facilitating subsequent collaborations based on research outcomes.
The event featured oral presentations sharing the progress of YIP projects, along with a research poster exhibition. Yuhan researchers and YIP scientists exchanged ideas related to research achievements and new drug development in a relaxed atmosphere, seeking collaboration opportunities.
During the 4th YIP, 13 new research projects were selected. Including projects from the first three rounds, a total of 76 research projects have received support to date.
CEO Joo Ok-je stated, "The new knowledge and creative ideas accumulated through basic research are the starting point and the most important driving force for innovative drugs. We will continue to seek new scientific possibilities through ongoing exchanges and expand the foundation for collaboration to create innovative drugs."
Meanwhile, open innovation is a strategy where pharmaceutical companies utilize external technologies and ideas from universities, research institutions, and biotech ventures to co-develop new drugs or connect through technology transfer, investment, and commercialization. Major pharmaceutical companies, including Yuhan, GC Green Cross, and SK Biopharm, are expanding their efforts in external technology acquisition, joint research, investment, and global commercialization to secure new drug pipelines.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.